Comprehensive characterization of PD-L1 expression and immunotherapy-related genomic biomarkers in early- versus advanced-stage non-small cell lung cancer
Abstract Background Programmed death-ligand 1 (PD-L1) expression is a key biomarker for predicting the efficacy of immune checkpoint inhibitors (ICIs). With the successful application of perioperative immunotherapy, understanding PD-L1-associated clinical and molecular characteristics in early-stage...
Saved in:
| Main Authors: | Yujie Chen, Peiyuan Wang, Rong Lian, Mingming Yuan, Pengli Yu, Hao He, Peng Chen, Hang Zhou, Weijie Chen, Derong Zhang, Hui Lin, Shuoyan Liu, Feng Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-025-03687-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Classification of lung cancer severity using gene expression data based on deep learning
by: Ali Bou Nassif, et al.
Published: (2025-05-01) -
Utilizing multi-omics analysis, a new signature has been identified and validated for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma, which is based on tumor mutation burden
by: Dongguang Wang, et al.
Published: (2025-04-01) -
The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma
by: Yuyan Xie, et al.
Published: (2024-12-01) -
Integrative analysis of single-cell and transcriptome sequencing with experimental validation reveals PKHD1L1 as a novel biomarker in lung adenocarcinoma
by: Xiangqian Zhang, et al.
Published: (2025-01-01) -
An updated review of immunotherapy in esophageal cancer: PD-L1 footprint
by: Juan Yao, et al.
Published: (2024-05-01)